Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.

Details

Serval ID
serval:BIB_50C9BDFD646C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
Journal
Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology
Author(s)
Joensuu H., Eriksson M., Collan J., Balk M.H., Leyvraz S., Montemurro M.
ISSN
1879-0887 (Electronic)
ISSN-L
0167-8140
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
116
Number
2
Pages
233-238
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
PURPOSE: Gastrointestinal stromal tumor (GIST) has been considered radiation-resistant, and radiotherapy is recommended only for palliation of bone metastases in current treatment guidelines. No registered prospective trial has evaluated GIST responsiveness to radiotherapy.
PATIENTS AND METHODS: Patients with GIST progressing at intra-abdominal sites or the liver were entered to this prospective Phase II multicenter study (identifier NCT00515931). Metastases were treated with external beam radiotherapy using either conformal 3D planning or intensity modulated radiotherapy and conventional fractionation to a cumulative planning target volume dose of approximately 40 Gy. Systemic therapy was maintained unaltered during the study.
RESULTS: Of the 25 patients entered, 19 were on concomitant tyrosine kinase inhibitor therapy, most often imatinib. Two (8%) patients achieved partial remission, 20 (80%) had stable target lesion size for ⩾3 months after radiotherapy with a median duration of stabilization of 16 months, and 3 (12%) progressed. The median time to radiotherapy target lesion progression was 4-fold longer than the median time to GIST progression at any site (16 versus 4 months). Radiotherapy was generally well tolerated.
CONCLUSIONS: Responses to radiotherapy were infrequent, but most patients had durable stabilization of the target lesions. GIST patients with soft tissue metastases benefit frequently from radiotherapy.
Keywords
Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Female, Gastrointestinal Neoplasms/drug therapy, Gastrointestinal Neoplasms/radiotherapy, Gastrointestinal Stromal Tumors/drug therapy, Gastrointestinal Stromal Tumors/radiotherapy, Humans, Male, Middle Aged, Prospective Studies, Protein Kinase Inhibitors/therapeutic use, Protein-Tyrosine Kinases/antagonists & inhibitors, Radiotherapy Planning, Computer-Assisted
Pubmed
Web of science
Open Access
Yes
Create date
17/11/2015 17:38
Last modification date
20/08/2019 14:06
Usage data